|  | annual rate of VL testing | Subjects having ≥ 1 gap of >9 months | Subjects having ≥ 1 gap of >6 months | |||
---|---|---|---|---|---|---|---|
Characteristics | N | median (IQR) | p value | # (%) | p value | # (%) | p value |
Overall | 3648 | 4.3 (3.4-5.5) | Â | 943 (26%) | Â | 1848 (51%) | Â |
Region | Â | Â | Â | Â | Â | Â | Â |
   BC | 1674 | 4.9 (3.8-6.3) | < .0001 | 347 (21%) | < .0001 | 672 (40%) | < .0001 |
   Ontario | 1143 | 3.9 (3.1-4.8) |  | 357 (31%) |  | 699 (61%) |  |
   Quebec | 831 | 4.0 (3.2-4.8) |  | 239 (29%) |  | 477 (57%) |  |
Age (years) | Â | Â | Â | Â | Â | Â | Â |
   ≤ 40 | 1942 | 4.1 (3.2-5.3) | < .0001 | 614 (32%) | < .0001 | 1122 (58%) | < .0001 |
   > 40 | 1706 | 4.5 (3.6-5.8) |  | 329 (19%) |  | 726 (43%) |  |
Gender | Â | Â | Â | Â | Â | Â | Â |
   Female | 723 | 3.9 (3.1-5.0) | < .0001 | 255 (35%) | < .0001 | 475 (66%) | < .0001 |
   Male | 2925 | 4.4 (3.5-5.7) |  | 688 (24%) |  | 1373 (47%) |  |
Caucasian | Â | Â | Â | Â | Â | Â | Â |
   No | 855 | 4.4 (3.4-5.7) | 0.33 | 255 (30%) | 0.04 | 463 (54%) | < .001 |
   Yes | 956 | 4.4 (3.4-5.9) |  | 244 (26%) |  | 439 (46%) |  |
Risk Factor | Â | Â | Â | Â | Â | Â | Â |
   IDU | 632 | 4.0 (3.0-5.1) | < .0001 | 247 (39%) | < .0001 | 417 (66%) | < .0001 |
   MSM | 976 | 4.3 (3.5-5.4) |  | 186 (19%) |  | 421 (43%) |  |
   Blood product recipient | 32 | 4.1 (3.5-5.1) |  | 8 (25%) |  | 18 (56%) |  |
   Endemic | 209 | 4.1 (3.4-4.8) |  | 60 (29%) |  | 128 (61%) |  |
   Heterosexual contact | 245 | 4.2 (3.4-5.7) |  | 64 (26%) |  | 135 (55%) |  |
   Not reported/Other | 1554 | 4.5 (3.4-5.8) |  | 378 (24%) |  | 729 (47%) |  |
AIDS defining illness | Â | Â | Â | Â | Â | Â | Â |
   No | 3167 | 4.2 (3.3-5.5) | < .0001 | 858 (27%) | < .0001 | 1641 (52%) | < .001 |
   Yes | 481 | 4.7 (3.8-5.9) |  | 85 (18%) |  | 207 (43%) |  |
Type of cART | Â | Â | Â | Â | Â | Â | Â |
   NNRTI-based | 1586 | 4.1 (3.2-5.0) | < .0001 | 425 (27%) | < .0001 | 874 (55%) | < .0001 |
   Boosted PI-based | 1433 | 5.0 (3.7-6.5) |  | 292 (20%) |  | 573 (40%) |  |
   Single PI-based | 384 | 4.0 (3.1-4.9) |  | 149 (39%) |  | 256 (67%) |  |
   Other cART | 245 | 3.9 (3.2-4.7) |  | 77 (31%) |  | 145 (59%) |  |
Year of initiating cART | Â | Â | Â | Â | Â | Â | Â |
   2000 | 482 | 3.7 (2.8-4.7) | < .0001 | 219 (45%) | < .0001 | 346 (72%) | < .0001 |
   2001-2004 | 2036 | 4.2 (3.3-5.3) |  | 599 (29%) |  | 1132 (56%) |  |
   >2004 | 1130 | 4.9 (3.9-6.4) |  | 125 (11%) |  | 370 (33%) |  |
CD4 count | Â | Â | Â | Â | Â | Â | Â |
   < 200 cells/mm3 | 1921 | 4.4 (3.4-5.7) | < .0001 | 474 (25%) | < .001 | 941 (49%) | < .0001 |
   200 - 350 cells/mm3 | 1175 | 4.3 (3.4-5.5) |  | 286 (24%) |  | 560 (48%) |  |
   > 350 cells/mm3 | 544 | 4.1 (3.0-5.2) |  | 181 (33%) |  | 341 (63%) |  |
VL (copies/mL) | Â | Â | Â | Â | Â | Â | Â |
   ≥ 50 | 3509 | 4.3 (3.4-5.6) | < .001 | 905 (26%) | 0.68 | 1770 (50%) | 0.19 |
   < 50 | 139 | 3.9 (2.9-4.8) |  | 38 (27%) |  | 78 (56%) |  |
Hepatitis C Co-infection | Â | Â | Â | Â | Â | Â | Â |
   No | 1712 | 4.4 (3.6-5.6) | < .0001 | 346 (20%) | < .0001 | 756 (44%) | < .0001 |
   Yes | 736 | 4.1 (3.0-5.3) |  | 281 (38%) |  | 473 (64%) |  |